COPENHAGEN, Aug 9 (Reuters) - Danish drugmaker Novo Nordisk said on Thursday it was seeing only a marginal impact on Victoza sales from rival diabetes treatment Bydureon in countries outside the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results